Research programme: protozoal infection therapeutics - aRigenAlternative Names: ARA-01; ARA-02; ARA-03; ARA-04
Latest Information Update: 24 Feb 2010
At a glance
- Originator aRigen
- Class Parasitic vaccines; Sesquiterpenes
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Protozoan infections
Most Recent Events
- 24 Feb 2010 Preclinical development is ongoing in Japan
- 07 Dec 2006 Preclinical trials in Protozoal infections in Japan (unspecified route)